Susan A. Oliveria
Research Subjects
Susan A. Oliveria has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Marianne Ulcickas Yood
EpiSource, LLC, Newton, MA, USA
3 shared publications - Ai-Lin Tsai
Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, USA
1 shared publication Bonnie M.K. Donato
Bristol-Myers Squibb Company, Wallingford, Connecticut, USA
1 shared publicationBruce D. McCarthy
Alina Medical Clinic, Woodbury, MN, USA
1 shared publication- Carol E. Koro
GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
1 shared publication - Charles P QuesenberryJr
Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States
1 shared publication
Latest Publications
- Open Access
- 15 December 2011
- Published by Springer Nature in BMC Psychiatry
- Vol. 11 (1) , 197
Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
Background: The benefits of some second-generation antipsychotics (SGAs) must be weighed against the increased risk for diabetes mellitus. This study examines whether the association between SGAs and diabetes differs by dose. Methods: Patients were ≥18 years of age from three US healthcare systems and exposed to an SGA for ≥45 days between November 1, 2002 and March 31, 2005. Patients had no evidence of diabetes before index date and no previous antipsychotic prescription filled within 3 months before index date. 49,946 patients were exposed to SGAs during the study period. Person-time exposed to antipsychotic dose (categorized by tertiles for each drug) was calculated. Newly treated diabetes was identified using pharmacy data to determine patients exposed to anti-diabetic therapies. Adjusted hazard ratios for diabetes across dose tertiles of SGA were calculated using the lowest dose tertile as reference. Results: Olanzapine exhibited a dose-dependent relationship for risk for diabetes, with elevated and progressive risk across intermediate (diabetes rate per 100 person-years = 1.9; adjusted Hazard Ratio (HR), 1.7, 95% confidence interval (CI), 1.0-3.1) and top tertile doses (diabetes rate per 100 person-years = 2.7; adjusted HR, 2.5, 95% CI, 1.4-4.5). Quetiapine and risperidone exhibited elevated risk at top dose tertile with no evidence of increased risk at intermediate dose tertile. Unlike olanzapine, quetiapine, and risperidone, neither aripiprazole nor ziprasidone were associated with risk of diabetes at any dose tertile. Conclusions: In this large multi-site epidemiologic study, within each drug-specific stratum, the risk of diabetes for persons exposed to olanzapine, risperidone, and quetiapine was dose-dependent and elevated at therapeutic doses. In contrast, in aripiprazole-specific and ziprasidone-specific stratum, these newer agents were not associated with an increased risk of diabetes and dose-dependent relationships were not apparent. Although, these estimates should be interpreted with caution as they are imprecise due to small numbers.
- 15 December 2011
- Published by Springer Nature in BMC Psychiatry
- Vol. 11 (1) , 197
Open AccessAssociation between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
Background: The benefits of some second-generation antipsychotics (SGAs) must be weighed against the increased risk for diabetes mellitus. This study examines whether the association between SGAs and diabetes differs by dose. Methods: Patients were ≥18 years of age from three US healthcare systems and exposed to an SGA for ≥45 days between November 1, 2002 and March 31, 2005. Patients had no evidence of diabetes before index date and no previous antipsychotic prescription filled within 3 months before index date. 49,946 patients were exposed to SGAs during the study period. Person-time exposed to antipsychotic dose (categorized by tertiles for each drug) was calculated. Newly treated diabetes was identified using pharmacy data to determine patients exposed to anti-diabetic therapies. Adjusted hazard ratios for diabetes across dose tertiles of SGA were calculated using the lowest dose tertile as reference. Results: Olanzapine exhibited a dose-dependent relationship for risk for diabetes, with elevated and progressive risk across intermediate (diabetes rate per 100 person-years = 1.9; adjusted Hazard Ratio (HR), 1.7, 95% confidence interval (CI), 1.0-3.1) and top tertile doses (diabetes rate per 100 person-years = 2.7; adjusted HR, 2.5, 95% CI, 1.4-4.5). Quetiapine and risperidone exhibited elevated risk at top dose tertile with no evidence of increased risk at intermediate dose tertile. Unlike olanzapine, quetiapine, and risperidone, neither aripiprazole nor ziprasidone were associated with risk of diabetes at any dose tertile. Conclusions: In this large multi-site epidemiologic study, within each drug-specific stratum, the risk of diabetes for persons exposed to olanzapine, risperidone, and quetiapine was dose-dependent and elevated at therapeutic doses. In contrast, in aripiprazole-specific and ziprasidone-specific stratum, these newer agents were not associated with an increased risk of diabetes and dose-dependent relationships were not apparent. Although, these estimates should be interpreted with caution as they are imprecise due to small numbers.
- 1 March 2010
- Published by Elsevier in Clinical Therapeutics
- Vol. 32 (3) , 546-554
Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: A descriptive report
- 1 March 2010
- Published by Elsevier in Clinical Therapeutics
- Vol. 32 (3) , 546-554
Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: A descriptive report
- 1 February 2008
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 2 (1) , 47-57
Cancer incidence among patients treated with antidiabetic pharmacotherapy
- 1 February 2008
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 2 (1) , 47-57
Cancer incidence among patients treated with antidiabetic pharmacotherapy
- 1 January 2007
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 23 (12) , 3105-3112
Barriers to the initiation of, and persistence with, insulin therapy
Objectives: Many patients with Type 2 diabetes mellitus (DM) delay and/or discontinue the use of insulin. This study determined patient-perceived barriers to the initiation of, and persistence with, insulin therapy.Research design and methods: Patients ≥ 18 years with Type 2 DM and ≥ 1 elevated HbA1c test result (≥ 9%) were identified from computerized laboratory test results within a single healthcare system, a study limitation. Insulin use patterns were characterized by automated pharmacy claims data, and patients were classified into those who discontinued insulin use (discontinuers) or those who did not initiate insulin use (non-initiators). Telephone interviews were conducted to determine the barriers to initiation of, and persistence with, insulin therapy.Results: Response rates were 80.0% (73/91) for discontinuers and 82.0% (129/157) for non-initiators. Pharmacy claims data indicated that discontinuers stopped filling prescriptions for insulin; 46.6% of patients self-reported discontinuing ...
- 1 January 2007
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 23 (12) , 3105-3112
Barriers to the initiation of, and persistence with, insulin therapy
Objectives: Many patients with Type 2 diabetes mellitus (DM) delay and/or discontinue the use of insulin. This study determined patient-perceived barriers to the initiation of, and persistence with, insulin therapy.Research design and methods: Patients ≥ 18 years with Type 2 DM and ≥ 1 elevated HbA1c test result (≥ 9%) were identified from computerized laboratory test results within a single healthcare system, a study limitation. Insulin use patterns were characterized by automated pharmacy claims data, and patients were classified into those who discontinued insulin use (discontinuers) or those who did not initiate insulin use (non-initiators). Telephone interviews were conducted to determine the barriers to initiation of, and persistence with, insulin therapy.Results: Response rates were 80.0% (73/91) for discontinuers and 82.0% (129/157) for non-initiators. Pharmacy claims data indicated that discontinuers stopped filling prescriptions for insulin; 46.6% of patients self-reported discontinuing ...